Plain-English translation of NCT06385730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called toripalimab, which works by helping your immune system fight cancer cells. You would receive this medication before surgery to remove your esophageal cancer. The trial is specifically designed for patients over 75 years old because previous cancer treatments have been too harsh for this age group.
Doctors currently use strong chemotherapy before surgery for advanced esophageal cancer, but research shows this treatment is too toxic for patients over 75 and doesn't improve survival for them. This trial is testing whether the new treatment is gentler and more effective for older adults.
You likely qualify if…
You likely don't qualify if…
You would receive the medication toripalimab through infusions before undergoing surgery to remove your esophageal cancer. Some participants will receive the medication alone, while others will receive it combined with low-dose radiation therapy. After completing this pre-surgery treatment phase, you would have your planned surgery. You would then be followed up to see how well the treatment worked and to monitor your recovery.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Chest Hospital
Enrollment target
~60 participants
Started
June 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
76 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhigang Li, MD, PhD
Shanghai Chest Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.